297 related articles for article (PubMed ID: 32212519)
1. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
[TBL] [Abstract][Full Text] [Related]
5. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
[TBL] [Abstract][Full Text] [Related]
6. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
[TBL] [Abstract][Full Text] [Related]
7. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
[TBL] [Abstract][Full Text] [Related]
8. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
[TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
Ackerman P; Thompson M; Molina JM; Aberg J; Cassetti I; Kozal M; Castagna A; Martins M; Ramgopal M; Sprinz E; Treviño-Pérez S; Streinu-Cercel A; Latiff GH; Pialoux G; Kumar PN; Wang M; Chabria S; Pierce A; Llamoso C; Lataillade M
AIDS; 2021 Jun; 35(7):1061-1072. PubMed ID: 33946085
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
Llibre JM; Aberg JA; Walmsley S; Velez J; Zala C; Crabtree Ramírez B; Shepherd B; Shah R; Clark A; Tenorio AR; Pierce A; Du F; Li B; Wang M; Chabria S; Warwick-Sanders M
Front Immunol; 2024; 15():1394644. PubMed ID: 38863717
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
15. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
Chahine EB
Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
[TBL] [Abstract][Full Text] [Related]
17. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Aberg JA; Shepherd B; Wang M; Madruga JV; Mendo Urbina F; Katlama C; Schrader S; Eron JJ; Kumar PN; Sprinz E; Gartland M; Chabria S; Clark A; Pierce A; Lataillade M; Tenorio AR
Infect Dis Ther; 2023 Sep; 12(9):2321-2335. PubMed ID: 37751019
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
19. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
[TBL] [Abstract][Full Text] [Related]
20. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
